Lee Schacter
57 works · 2,902 citations · h-index 24
Top works
- A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
- Managing Attribute-Value Clinical Trials Data Using the ACT/DB Client-Server Database System
- Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
- Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.
- Anagrelide: A New Drug for Treating Thrombocytosis
- ANTAGONISM BETWEEN MICONAZOLE AND AMPHOTERICIN B
- Effect of conditioned media on differentiation in mass cultures of chick limb bud cells
- The pleiotypic response in mammalian cells: Search for an intracellular mediator
- Etoposide phosphate: what, why, where, and how?
- A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.
- Protracted Infusion of 5-FU with Weekly Low-Dose Cisplatin as Second-Line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed 5-FU Monotherapy
- Reengineering a Database for Clinical Trials Management
- Overview of Phase I Trials of 2′,3′-Dideoxyinosine (ddI) Conducted on Adult Patients
- Overview of hormonal therapy in advanced breast cancer.
- Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma
- Megestrol acetate: clinical experience
- Fatal radiation hepatitis: A case report and review of the literature
- Effect of Conditioned Media on differentiation in mass cultures of chick limb bud cells
- Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
- Red cell superoxide dismutase and sickle cell anemia symptom severity